

№492, 28-fevral, 2022 y.

COVID-19 ga qarshi vaksinalarning  
ishlanmalari bo'yicha

**DAYJEST**

O'zbekiston Respublikasi Innovatsion rivojlanish vazirligi huzuridagi  
Ilmiy-texnik axborot markazi











Toshkent-2022

# Jahonda pandemiya bilan bog'liq vaziyat

2022 y. 27-fevral holatiga ko'ra

Umumiy zararlanganlar soni	-	436 662 731	(+ 1 306 537)
Sog'ayganlar soni	-	364 655 257	(+ 1 720 865)
Vafot etganlar soni	-	5 963 138	(+ 6 528)

## Mamlakatlar bo'yicha bemorlar soni


	AQSh	-	80 560 293	(+ 26 003)
	Hindiston	-	42 916 117	(+ 10 273)
	Braziliya	-	28 744 050	(+ 72 856)
	Fransiya	-	22 646 732	(+ 53 623)
	Buyuk Britaniya	-	18 804 765	(+ 39 656)
	Rossiya	-	16 175 023	(+ 122 995)
	Germaniya	-	14 633 511	(+ 129 360)
	Turkiya	-	13 975 389	(+ 61 764)
	Italiya	-	12 732 680	(+ 38 375)
	O'zbekiston	-	236 405	(+ 106)

Manba: <https://www.worldometers.info/coronavirus/>




# O'zbekistonda pandemiya bilan bog'liq vaziyat

2022 y. 27-fevral holatiga ko'ra



Yanvar 2022-yil



Fevral 2022 yil



# O'zbekistonda COVID-19 qarshi vaksinatsiya bo'yicha hisobot

2022 y. 26-yanvar holatiga ko'ra

Hududlar	Jami emlanganlar soni	Bir kunda emlanganlar soni
Qoraqalpog'iston Respublikasi	2 277 697	3 436
Andijon viloyati	4 509 462	16 105
Buxoro viloyati	2 520 168	5 645
Jizzax viloyati	1 584 930	4 243
Qashqadaryo viloyati	3 671 953	13 175
Navoiy viloyati	1 434 978	3 321
Namangan viloyati	4 200 966	1 993
Samarqand viloyati	5 374 518	9 797
Surxondaryo viloyati	3 614 494	8 137
Sirdaryo viloyati	1 016 022	5 488
Toshkent viloyati	4 304 529	21 178
Farg'ona viloyati	4 936 321	9 345
Xorazm viloyati	2 703 746	5 105
Toshkent sh.	3 606 730	9 145
<b>Jami</b>	<b>45 756 511</b>	<b>116 113</b>

Manba: SSV matbuot kotibi // <https://t.me/ssvmatbuotkotibi>



# JSST tomonidan baholash jarayonida COVID-19 ga qarshi vaksinlarning holati

2022 y. 25-fevral holatiga ko'ra

№	Ishlab chiqaruvchi	Vaksina nomi	Platforma	Arizalarni qabul qilish	Uchrashuv o'tkazish	Ma'lumotnomani ko'rib chiqish uchun qabul qilish	Baholash holati	Kutilayotgan chiqish sanasi
1	Pfizer	BNT162b2/COMIRNATY	mRNA	+	+	+	Yakunlangan	Tasdiqlangan 31.12.2020
2	AstraZeneca/University of Oxford	AZD1222	Recombinant replication defective chimpanzee adenovirus expressing surface glycoprotein SARS-CoV-2	+	+	+	Yakunlangan	Tasdiqlangan 15.02.2021
3	Janssen	Ad26.COV2.S	Recombinant vector vaccine against adenovirus type 26 (Ad26), incapable of replication, encoding Spike (S) protein (SARS-CoV-2)	+	+	+	Yakunlangan	Tasdiqlangan 12.03.2021
4	SK BIOscience - AstraZeneca/University of Oxford	AZD1222	Recombinant adenoviral vector ChAdOx1 encoding the Spike SARS-CoV-2 protein antigen	+	+	+	Yakunlangan	Tasdiqlangan 16.04.2021
5	Serum institute of India	Covishield	mRNA-based vaccine encapsulated in lipid nanoparticles	+	+	+	Yakunlangan	Tasdiqlangan 30.04.2021
6	Moderna	mRNA-1273	Inactivated, produced in Vero cells	+	+	+	Yakunlangan	Tasdiqlangan 07.05.2021
7	Sinopharm / BIBP	SARS-CoV-2 Vaccine (Vero Cell), Inactivated (InCoV)	Inactivated, produced in Vero cells	+	+	+	Yakunlangan	Tasdiqlangan 01.06.2021
8	Sinovac	SARS-CoV-2 Vaccine (Vero Cell), Inactivated	Protein subunit virus-like particle vaccine	+	+	+	Yakunlangan	Tasdiqlangan 17.12.2021
9	Novavax	NVX-CoV2373, Covovax, Nuvaxovid						


Manba:

Status of COVID-19 Vaccines within WHO EUL // [https://extranet.who.int/pqweb/sites/default/files/documents/Status\\_COVID\\_VAX\\_20Oct2021.pdf](https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_20Oct2021.pdf)



# Vaksinani tasdiqlagan va undan foydalanilayotgan mamlakatlar soni

2022 y. 25-fevral holatiga ko'ra



Manbalar:

\*Approved or Authorized Vaccines // [https://  
COVID-19 Vaccine Market Dashboard //](https://www.unicef.org/supply/covid-19-vaccine-market-dashboard)

<https://www.unicef.org/supply/covid-19-vaccine-market-dashboard>

\*\*Tracking Coronavirus Vaccinations Around the World //


<https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html>



# Mamlakatlar va kontinentlar kesimida COVID-19 ga qarshi emlanganlar soni

2022 y. 25-fevral holatiga ko'ra

№	Davlatlar	Emlanganlar soni		Aholining umumiy sonida emlanganlarning ulushi	
		100 ta kishiga	Jami	Bitta doza bilan emlangan	To'liq emlangan
	<b>Dunyo</b>	<b>138</b>	<b>10 571 030 651</b>	<b>64%</b>	<b>56%</b>
1	BAA	246	23 992 173	99%	97%
2	Bruney	226	979 285	94%	93%
3	Portugaliya	220	22 638 919	94%	91%
4	Kuba	307	34 849 139	94%	87%
5	Chili	252	47 767 408	93%	90%
6	Malta	246	1 236 598	93%	92%
7	Xitoy	221	3 084 712 000	91%	88%
8	Argentina	205	92 275 649	89%	80%
9	Kambodja	208	34 299 633	87%	84%
10	Ispaniya	196	92 121 948	87%	82%




Manba:  
Tracking Coronavirus Vaccinations Around the World // <https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html>



# COVID-19 ga qarshi vaksinalarning narxi

2022 y. 25-fevral holatiga ko'ra

No	Vaksinaning ishlab chiqaruvchisi	Vaksinalarning narxi (bitta doza uchun)*
1	Pfizer	\$6,75-22,94
2	AstraZeneca/University of Oxford	\$2,19-5
3	Serum institute of India	\$3-13,27
4	Sinopharm	\$144,27 (2 ta doza uchun)
5	Sinovac	\$10,30-29,75
6	Moderna	\$15-37
7	Janssen	\$8,50-10
8	The Gamaleya National Center (Sputnik V)	\$11-19,90



Manba:

\* COVID-19 Vaccine Market Dashboard //

[https://www.unicef.org/supply/covid-19-vaccine-market-](https://www.unicef.org/supply/covid-19-vaccine-market-dashboard?utm_source=facebook&utm_medium=organic&utm_campaign=coronavirus&fbclid=IwAR101804JupyKfUU1u6osTc-nNVGj7kiYDI8eJtiMUgjEIALGhYO3w0EE)

[dashboard?utm\\_source=facebook&utm\\_medium=organic&utm\\_campaign=coronavirus&fbclid=IwAR101804JupyKfUU1u6osTc-nNVGj7kiYDI8eJtiMUgjEIALGhYO3w0EE](https://www.unicef.org/supply/covid-19-vaccine-market-dashboard?utm_source=facebook&utm_medium=organic&utm_campaign=coronavirus&fbclid=IwAR101804JupyKfUU1u6osTc-nNVGj7kiYDI8eJtiMUgjEIALGhYO3w0EE)



# Moderna vaksinasining Omicron shtammiga qarshi samaradorligi bo'yicha o'tkazilgan tadqiqotning oraliq natijalari e'lon qilindi

2022-yil 21-fevralda "Nature Medicine" jurnalida Amerika konsorsiumi tomonidan o'tkazilgan "Kaiser Permanente" kompleks sog'liqni saqlash bo'yicha yangi tadqiqotlar natijalariga ko'ra, Moderna COVID-19 vaksinasi koronavirusning "Delta" infeksiyasiga qarshi samarali himoyani ta'minlashi, ammo "Omicron" variantiga qarshi kamroq samarali ekanligi to'g'risida chop etildi [6].

Moderna COVID-19 vaktsinasining uchta dozasi Omicron yoki Delta variantidan kelib chiqqan infeksiya tufayli kasalxonaga yotqizishda yuqori samarali ekanligi aniqlandi.

Ushbu tadqiqot Janubiy Kaliforniyadagi Kaiser Permanente irqiy va etnik jihatdan turli a'zolar o'rtasida 2021-yil 6 va 31-dekabr kunlari yig'ilgan namunalarda yordamida o'tkazildi [7].



Unga COVID-19 uchun ijobiy sinovdan o'tgan 26,683 bemor, ularning 16% delta infeksiyasi va 84% omikron infeksiyasi, hamda taqqoslash guruhi sifatida salbiy testdan o'tgan 67,000 dan ortiq bemorni o'z ichiga oldi. Namunalarda, birinchi navbatda, COVID-19 alomatlari mavjud fuqarolardan nazofarengal yoki orofaringeal tamponlar

va asemptomatik bo'lgan odamlardan so'lak yordamida to'plangan.

Moderna COVID-19 vaksinasining ikki dozasi bilan emlashdan keyingi 3 oygacha Omicron infeksiyasiga qarshi 44% samarali bo'ldi, shundan so'ng samaradorlik tezda pasaydi. Moderna COVID-19 vaksinasining uch dozasi emlashdan keyin 2 oy ichida delta infeksiyasiga qarshi 94% va omicron infeksiyasiga qarshi 72% samarani ko'rsatdi.

Immunitet tizimi zaif bo'lgan shaxslar uchun Omicron infeksiyasiga qarshi uchta dozaning samaradorligi 29% pastroq ko'rsatkichga ega bo'lgan. "Omicron" yoki "Delta" shtammlari bilan kasalxonaga yotqizishga qarshi 3 dozaning samaradorligi 99% dan yuqori edi.

Uning qo'shimcha qilishicha, "3 doza Omicron yoki Delta varianti tufayli COVID-19 kasalxonaga yotqizishdan kuchli himoya qiladi" [8].



# Kanada o'simlikka asoslangan dunyodagi birinchi COVID-19 vaksinasini tasdiqladi

Kanada sog'liqni saqlash tashkiloti Kanadada ishlab chiqarilgan birinchi COVID-19 vaksinasini va inson foydalanish uchun dunyodagi birinchi o'simlik vaksinasini tasdiqladi. Covifenz Kvebekdagi Medicago biotexnologiya kompaniyasi tomonidan Britaniya-Amerika farmatsevtika giganti GlaxoSmithKline bilan hamkorlikda ishlab chiqilgan. 18 yoshdan 64 yoshgacha bo'lgan kattalarda foydalanish uchun tasdiqlangan [9].



“Bizning COVID-19 vaksinamizning ma’qullanishi Kanada uchun pandemiyaga qarshi kurashda muhim bosqich bo’ldi. Biz Health Canada tomonidan tezkor ko’rib chiqilgani uchun minnatdormiz”, dedi Medicago prezidenti va bosh direktori Takashi Nagao. “Biz Kanada hukumatiga ushbu yangi vaksinani ishlab chiqishni qo’llab-quvvatlagani uchun minnatdormiz va ular buyurgan dozalarni allaqachon ishlab chiqarishni boshladik” [10].

Kanada sog'liqni saqlash qarori 2021-yil aprel oyida boshlangan bosqichma-bosqich jarayon orqali Medicago tomonidan taqdim etilgan ilmiy dalillarga asoslangan. Klinik sinov natijalariga ko'ra, vakcina odamlarni COVID-19 ning og'ir ta'siridan himoya qilishda 71% samarali bo'lgan va Delta variantiga nisbatan samaradorlik darajasi 75% dan oshgan. Kanada sog'liqni saqlash vazirligi vaksinani 21 kunlik interval bilan ikki dozada qo'llashni tavsiya qildi.

Covifenz koronavirusga o'xshash zarrachalar (CoVLP) texnologiyasidan foydalanilgan. Vakcina virusga o'xshash zarrachalar shaklida ifodalangan rekombinant boshqoq (S) glikoproteindan iborat bo'lib, u pandemiya GSK yordamchisi bilan birgalikda qo'llaniladi. Emlash taqvimini 21 kunlik interval bilan ikkita dozada mushak ichiga yuboriladi (bir inyeksiyada 3,75 mkg CoVLP antigeni va GSK pandemik yordamchisi). Vakcina 2 ° C dan 8 ° C gacha bo'lgan haroratda saqlanadi. Kovifens antigeni Kanada va Shimoliy Karolinada (AQSH) ishlab chiqariladi [11, 12].

Bu Kanadada Moderna, Pfizer-BioNTech, AstraZeneca, Janssen va Novavaxdan keyin mamlakatda tasdiqlangan oltinchi COVID-19 vaksinasidir.

# Yevropa Ittifoqi 12 yoshdan oshgan o‘smirlar uchun Comirnaty vaksinasining kuchaytiruvchi dozasi tasdiqladi

Yevropa Tibbiyot Agentligi (EMA) zarurat tug‘ilganda 12 yosh va undan katta o‘smirlarni emlash uchun BioNTech va Pfizerning Comirnaty vaksinasining kuchaytiruvchi dozasi qo‘llash bo‘yicha tavsiyani ma‘qulladi. Bu haqda 24-fevral payshanba kuni Yevropa regulyatorining chop etilgan bayonotida ma‘lum qilindi [13].



“Vaksinaning odamlarga (ya‘ni birlamchi emlashni tugatganlarga) vaqt o‘tishi bilan pasayib ketadigan himoya darajasini tiklash uchun kuchaytiruvchi doza beriladi”, deb ta‘kidladi EMA. O‘smirlarda kuchaytiruvchi dozaga immun javobi hech bo‘lmaganda kattalarniki bilan bir xil bo‘ladi degan xulosaga keldi. Mavjud ma‘lumotlarga

asoslanib, yangi xavfsizlik muammolari aniqlanmagan”.

Amerikaning Pfizer kompaniyasi va uning nemis hamkori BioNTech tomonidan ishlab chiqilgan Comirnaty vaksinasi hozirda Yevropa Ittifoqida kattalar va besh yoshdan bolalarni birlamchi emlash, shuningdek, 12 yoshdan kattalar va o‘smirlar uchun kuchaytiruvchi doza sifatida tavsiya etiladi.



Bundan tashqari, EMA qo‘mitasi Moderna kompaniyasining Spikevax bilan emlash uchun 6-11 yoshli bolalarda foydalanish bo‘yicha arizasini tasdiqlashni tavsiya qildi. Bu endi Yevropa Ittifoqida kattalar va 6 yoshdan oshgan bolalarni birlamchi emlash, shuningdek, kattalarni kuchaytiruvchi doza uchun tasdiqlangan [14].



# Rossiyada COVID-19 ning uchta shtammi asosida vaktsina ishlab chiqilmoqda



N.F. Gamaleya nomidagi Epidemiologiya va mikrobiologiya ilmiy-tadqiqot markazida uchta shtamm “Wuhan”, “Delta” va “Omicron”ning S-oqsil elementlarini o‘z ichiga olgan virusga o‘xshash zarrachalarga asoslangan koronavirusga qarshi vaktsina ishlab chiqilgan. Bu haqda muassasa direktori Aleksandr Gintsburg ma’lum qildi [15].

Uning ta’kidlashicha, vaktsina COVID-19 doimiy mutatsiyasi sharoitida juda dolzarb bo‘ladi. Agar bir vaqtning o‘zida bir nechta koronavirus shtamlari aylanadigan bo‘lsa, uning tarkibiga yangi antigenik variantlarni kiritish juda oson bo‘ladi. Bu hozirgi “delta” “omikron” bilan birga infeksiyalangan holatlarda




kuzatilmoqda, - deya tushuntirdi olim.



Sog‘liqni saqlash vazirligi 18 yoshdan 55 yoshgacha bo‘lgan fuqarolar uchun preparatni klinik sinovlarining birinchi va ikkinchi bosqichlarini o‘tkazishni tasdiqladi. Sinovlarning birinchi va ikkinchi bosqichlarini yakunlash uchun uch yarim oydan to‘rt oygacha vaqt ketadi. Vaktsina Rossiyada agar tadqiqotlar muvaffaqiyatli

bo‘lsa, kuzgacha fuqarolik muomalasida ruxsat etilishi mumkin, dedi Gunzburg.

Gamaleya markazi mutaxassislari tomonidan ishlab chiqilgan monoklonal antitanalar asosidagi koronavirus preparatining klinik sinovlarini o‘tkazish uchun yaqin vaqt ichida ruxsat olish kerakligi avval xabar qilingan edi [16].



# Manbalar

1. Reported Cases and Deaths by Country, Territory, or Conveyance // <https://www.worldometers.info/coronavirus/> (27.02.2022)
2. Approved or Authorized Vaccines // <https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html> (25.02.2022)
3. COVID-19 Vaccine Market Dashboard // <https://www.unicef.org/supply/covid-19-vaccine-market-dashboard> (25.02.2022)
4. Tracking Coronavirus Vaccinations Around the World // <https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html> (25.02.2022)
5. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants // <https://www.nature.com/articles/s41591-022-01753-y> (27.02.2022)
6. Study looks at Moderna COVID-19 vaccine effectiveness // <https://about.kaiserpermanente.org/our-story/health-research/news/study-looks-at-moderna-covid-19-vaccine-effectiveness> (27.02.2022)
7. Study looks at Moderna COVID-19 vaccine effectiveness // <https://medicalxpress.com/news/2022-02-moderna-covid-vaccine-effectiveness.html> (27.02.2022)
8. Исследование эффективности вакцины Модерна против Омикрона: результаты // <https://kurer-sreda.ru/2022/02/25/776379-issledovanie-rassmatrivaet-effektivnost-vakciny-moderna-protiv-covid-19> (27.02.2022)
9. Medicago and GSK announce the approval by Health Canada of COVIFENZ®, an Adjuvanted Plant-Based COVID-19 Vaccine // <https://medicago.com/en/press-release/covifenz/> (27.02.2022)
10. Health Canada approves first made-in-Canada COVID-19 vaccine // <https://toronto.citynews.ca/2022/02/24/covifenz-made-in-canada-vaccine/> (27.02.2022)
11. Medicago Covifenz COVID-19 vaccine // <https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/vaccines/medicago.html> (27.02.2022)
12. Medicago и GSK сообщают об одобрении Министерством здравоохранения Канады COVIFENZ®, адьювантной вакцины от COVID-19 на растительной основе // <https://www.interfax.ru/pressreleases/824475> Регулятор ЕС одобрил бустерную дозу вакцины Comirnaty для подростков с 12 лет // <https://tass.ru/obschestvo/13843589> (27.02.2022)
13. European Medicines Agency recommends Pfizer booster for children over 12 // <https://www.thejournal.ie/european-medicines-agency-pfizer-booster-children-5692704-Feb2022/> (27.02.2022)
14. Вакцину на основе трех штаммов COVID-19 разрабатывают в России // [https://www.inform.kz/ru/vakcinu-na-osnove-treh-shtammov-covid-19-razrabatyvayut-v-rossii\\_a3903954](https://www.inform.kz/ru/vakcinu-na-osnove-treh-shtammov-covid-19-razrabatyvayut-v-rossii_a3903954) (27.02.2022)
15. Гинцбург анонсировал вакцину на основе частиц разных штаммов COVID-19 // <https://iz.ru/1292054/2022-02-16/gintzburg-zaiavil-o-skorom-issledovanii-kokteilia-iz-antitel-ot-covid-19> (27.02.2022)





O'zbekiston Respublikasi Innovatsion rivojlanish vazirligi huzuridagi  
Ilmiy-texnik axborot markazi

Toshkent-2022